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As a University of London undergraduate beginning a module on
pathology, I remember Professor Frank Fairweather opening his
lecture by pointing to a large boil on his forehead as an example
of acute inflammation. He then proceeded to describe the gross
pathological characteristics of acute inflammation: weal, brief
blood vessel constriction, followed by blood vessel dilation and
associated redness. Such was my introduction to the most com-
mon consequence of tissue damage—and contributor to disease
pathogenesis—inflammation.
Inflammation is mediated by chemical activators, collectively
known as chemokines, secreted in the area of the tissue damage.
Chemotactant proteins are expressed on the endothelial cell of
the dilated blood vessels that serve as recruitment factors for
lymphocytes. Blood vessel dilation causes a decrease in local
blood flow, and activated neutrophils, attracted by the chemo-
kines, attach to the chemotactant proteins, squeeze themselves
through the endothelial cell walls of the locally dilated blood
vessels, and follow the scent of the chemokines to the site of
damage (for additional information, see Schmidt 2005). 
Toxicogenomics has led to an additional description of
inflammation based on the differential expression of genes associ-
ated with the inflammatory process. One of the first toxicoge-
nomics reports published was that of the differential expression of
genes in response to lipopolysaccharide-induced inflammation
(Heller et al. 1997). Several reports now link the expression of
certain genes, in particular the attachment genes Vcam1 and
Icam1, to, for example, inflammation in the liver (Davies et al.
2005; Gant et al. 2003; Huang et al. 2004; Jiang et al. 2004). To
date, a quantitative fingerprint of gene expression associated with
inflammation has not been defined. In the GeneOntology (GO)
database (GO 2005), genes associated with, but not necessarily
quantitative for, inflammation are identified in biological
processes as “inflammatory response.” Under inflammatory
response in the GO, there are 371 genes listed for Homo sapiens.
Tumor necrosis factor-α (TNF-α) is included among these 362
genes, but interleukin 6 (IL-6) is not, although IL-6 is used as a
plasma biomarker of inflammation (Curran et al. 2005).
Similarly, a recent study in the liver has associated three genes
PGS6 (pregnancy-specific β-1-glycoprotein), GSTM4/M2 (glu-
tathione S-transferase mu 4 and mu 2), and OAT (ornithine
ketoacid aminotransferase) with inflammation in human liver
(Younossi et al. 2005); these genes, like IL-6, are not categorized
as inflammation genes in the GO. Thus, not all genes associated
with inflammation are defined as such in GO, and none are
quantitatively associated. Therefore, to provide a repository of
data for making future associations, we need a maintained sub-
database of differential gene expressions that are quantitatively
associated with measured pathological responses. Such quantita-
tive association of gene expression with altered pathology,
known as “phenotypic anchoring” (Moggs 2005; Moggs et al.
2004; Paules 2003; Waters and Fostel 2004), includes measure-
ment of both gene expression and degree of pathological
change. Few data sets in Gene Expression Omnibus (GEO
2005) or ArrayExpress (European Bioinformatics Institute 2005)
contain a histopathological quantitation of
inflammation of sufficient quality to allow
retrospective phenotypic anchoring of dif-
ferential gene expression at the present
time. More data sets need to include an
actual measure of pathological change. In particular, toxicoge-
nomic data should be collected before and during the onset of
measured pathological change.
However, before embarking on the development of a pheno-
typically anchored database of signature gene expression, we must
ask the following question: Does toxicogenomics have any advan-
tage over histopathology in the assessment and characterization of
pathological change? For inflammation, as for other pathologies,
the answer to this question depends on whether toxicogenomics
can a) detect inflammation before it becomes histopathologically
observable, b) provide a more quantitative assessment of its sever-
ity, and c) distinguish between the acute and chronic forms and
other pathologies. If we are referring to the most informative genes,
the answer to these questions is probably “yes,” but more data is
necessary to derive conclusive answers. Thus, the generation of
more gene expression data is necessary in targeted pathologies such
as inflammation, and a phenotypically anchored database should
be targeted to specific common pathologies in the first instance so
critical data masses of gene expression data can be collected.
In the early development of microarrays and their application
in toxicology, some predictions were made that histopathologists
would become an endangered species, made redundant by the
new technology. This has not happened, and even the reverse
could be argued to have occurred; toxicogenomics has proven so
challenging for interpretation that there has been a retreat into
the “gold standard” methods of analysis (Albertini 2005).
Toxicogenomics has the potential to inform and append
histopathological assessment, injecting a degree of instrumental
precision into the analysis and assisting in the differentiation of
difficult-to-discern lesions (Gant 2002, 2003; Lakhani and
Ashworth 2001). Although there is still much work to be done,
toxicogenomics will gradually gain a central role in the toxi-
cologists’ armory—as long as expectations are reasonable, quality
is good, interpretation is expert, and conclusions are balanced.
Genomics has much to offer in pathological assessment, but its
application should be collaborative, not inflammatory.
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Environmental Health Perspectives (EHP) is like one of the
lighthouses that dot the North Carolina coast; the journal acts
as a beacon warning people of potential environmental dangers
and, at the same time, welcomes people whose goal is to
improve global health. Although we report areas of concern
about how our environment can negatively affect us, we also
provide information that can give a sense of hope for the
improvement of human health. Regardless of the information
to be shared, EHP tries to provide the balance between voices
that sometimes have competing interests.
I will be retiring at the end of December and have been
blessed to have a fulfilling career dating back to 1969 that
allowed me to experience industrial, academic, and govern-
mental service. Along the way I have had the honor to work
with many wonderful people. However, none of my experi-
ences has been more fulfilling than my time at NIEHS during
which I served with the National Toxicology Program and now
with EHP. The talent, energy, tenacity, and altruism of these
wonderful people are beyond compare.
NIEHS has been the benevolent sponsor of EHP since
its inception over 30 years ago. NIEHS is an exceptional insti-
tution with exceptional people, who are at the forefront of
research in environmental health issues. During this time
EHP has given a voice to the institute and to the field of envi-
ronmental health. 
Although the future sponsorship of EHP is uncertain, the
journal will continue in its mission of serving “as a forum for
the discussion of the interrelationships between the environ-
ment and human health by publishing in a balanced and
objective manner the best peer-reviewed research and most
current and credible news of the field.” 
My immediate plans are to go on extended camping trips
across the United States with my wife, Marilyn (who is not
just another pretty face!). I hope to use this time to contem-
plate new ways to contribute to scientific capacity building
and information dissemination in the developing world,
which has been my passion at EHP. I am very grateful for, and
will always remember, the support and dedication of the EHP
staff and the NIEHS administration during my tenure.
Thomas J. Goehl
Editor-in-Chief, EHP
National Institute of Environmental Health Sciences
National Institutes of Health
Department of Health and Human Services
Note from the Editor:
Good Bye and Thank You
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